Ganellin C R, Blakemore R C, Brown T H, Cooper D G, Durant G J, Harvey C A, Ife R J, Owen D A, Parsons M E, Rasmussen A C
N Engl Reg Allergy Proc. 1986 Mar-Apr;7(2):126-33. doi: 10.2500/108854186779047762.
SK&F 93319 (icotidine), 2-[4-(3-methoxypyrid-2-yl)butylamino]-5-[(6-methylpyrid-3-yl )-methyl]- pyrimidin-4-one trihydrochloride, has been identified as a novel agent which combines into one molecule the ability to antagonize the actions of histamine at H1 and H2 receptors across a similar concentration or dose range. The degree of antagonism of vascular responses to histamine exceeds that possible with either an H1- or H2-receptor histamine antagonist alone. SK&F 93319 may have therapeutic utility in conditions requiring simultaneous antagonism of histamine at H1 and H2 receptors.
SK&F 93319（异可替丁），即2-[4-(3-甲氧基吡啶-2-基)丁基氨基]-5-[(6-甲基吡啶-3-基)甲基]-嘧啶-4-酮三盐酸盐，已被鉴定为一种新型药物，它在相似的浓度或剂量范围内，将组胺H1和H2受体的拮抗作用结合于一个分子中。对组胺血管反应的拮抗程度超过单独使用H1或H2受体组胺拮抗剂所能达到的程度。SK&F 93319在需要同时拮抗组胺H1和H2受体的病症中可能具有治疗作用。
